Announcements Trials
Browse Landscape

Phase

Phase 2 163Phase 3 92Phase 1 28Phase 1/2 22Phase 4 20Phase NA 12Phase EARLY_PHASE1 7Phase 2/3 6

Status

Unknown 3Completed 2Terminated 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6

Conditions

Breast Neoplasms 6Endometrial Neoplasms 4Progesterone Resistance 2Polycystic Ovary Syndrome 2Endometrial Hyperplasia 2Uterine Neoplasms 1Obesity 1Neoplasm Metastasis 1Inflammatory Breast Neoplasms 1Infertility 1Hydatidiform Mole 1Hormone Receptor Positive HER-2 Negative Breast Cancer 1Gestational Trophoblastic Disease 1Cystadenocarcinoma, Serous 1Carcinoma, Ductal, Breast 1Breast Diseases 1

Interventions

Capecitabine 16Paclitaxel 12Docetaxel 10Cyclophosphamide 10Epirubicin 8Gemcitabine 7Letrozole 6Doxorubicin 6Carboplatin 6Trastuzumab 5Vinorelbine 4Cisplatin 4pertuzumab 3exemestane 3Neoadjuvant Therapy 3Drug Therapy 3Ado-Trastuzumab Emtansine 3AC protocol 3130-nm albumin-bound paclitaxel 3apatinib 2Zoledronic Acid 2Thiotepa 2Taxes 2Tamoxifen 2Standard of Care 2Radiosurgery 2Melatonin 2Lapatinib 2Injections 2Goserelin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2/3 × Breast Neoplasms × Letrozole × Clear all
NCT05523609 2023-12-01

Vitamin D and Calcium Supplementation in Breast Cancer

Tanta University

Phase 2/3 Unknown
40 enrolled
Breast

Breast Neoplasms

NCT03507465 2018-04-25

Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer

Guangdong Provincial People's Hospital

Phase 2/3 Unknown
290 enrolled
Breast

Breast Neoplasms

NCT03373708 2017-12-18

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

Shandong Cancer Hospital and Institute

Phase 2/3 Unknown
200 enrolled
Breast

Breast Diseases, Breast Neoplasms

NCT00684216 2017-09-14

Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

The Netherlands Cancer Institute

Phase 2/3 Terminated
10 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00535418 2017-09-05

Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers

Novartis

Phase 2/3 Completed
35 enrolled
Breast

Breast Neoplasms

NCT00333047 2009-11-19

Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy

Novartis

Phase 2/3 Completed
24 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡